MWA CONSULTING, INC.
  • Home
  • About MWA
  • Consulting Services
  • Industry News
  • Resource Center
    • Webinars
    • Blogs
    • Podcasts
  • Consulting Opportunities
  • Contact Us
  • Privacy Policy
Select Page

Inspection of Injectable Products for Visible Particulates: Draft Guidance for Industry

Dec 22, 2021

FROM THE INTRODUCTION: Visible particulates in injectable products can jeopardize patient safety. This guidance addresses the development and implementation of a holistic, risk-based approach to visible particulate control that incorporates product development,...

Stay current with FDA regulatory news and compliance trends!

Follow MWA on LinkedIn:

Recent Posts

  • FDA’s Informed Consent Regulations for Clinical Investigations
  • Quality Systems, Part 2: Developing Effective CAPAs
  • FDA’s Published Guidance from CDER Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality
  • FDA Fiscal Year 2022 Report on the State of Pharmaceutical Quality
  • What is GxP in pharma?

Designed by Elegant Themes | Powered by WordPress